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“Nothing in biology makes sense except in the light of evolution” 
 
Theodosius Dobzhansky 
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Summary 
 
 
From the beginning of the 20th century the world population has been 
confronted with the human immune deficiency virus 1 (HIV-1). This virus has the 
particularity to mutate fast, and could thus evade and adapt to the human host. Our 
closest evolutionary related organisms, the non-human primates, are less susceptible 
to HIV-1. In a broader sense, primates are differentially susceptible to various 
retrovirus. Species specificity may be due to genetic differences among primates. In 
the present study we applied evolutionary and comparative genetic techniques to 
characterize the evolutionary pattern of host cellular determinants of HIV-1 
pathogenesis. The study of the evolution of genes coding for proteins participating to 
the restriction or pathogenesis of HIV-1 may help understanding the genetic basis of 
modern human susceptibility to infection.  
To perform comparative genetics analysis, we constituted a collection of 
primate DNA and RNA to allow generation of de novo sequence of gene orthologs. 
More recently, release to the public domain of two new primate complete genomes 
(bornean orang-utan and common marmoset) in addition of the three previously 
available genomes (human, chimpanzee and Rhesus monkey) help scaling up the 
evolutionary and comparative genome analysis. Sequence analysis used 
phylogenetic and statistical methods for detecting molecular adaptation. 
We identified different selective pressures acting on host proteins involved in 
HIV-1 pathogenesis. Proteins with HIV-1 restriction properties in non-human primates 
were under strong positive selection, in particular in regions of interaction with viral 
proteins. These regions carried key residues for the antiviral activity. Proteins of the 
innate immunity presented an evolutionary pattern of conservation (purifying 
 2
selection) but with signals of relaxed constrain if we compared them to the average 
profile of purifying selection of the primate genomes. Large scale analysis resulted in 
patterns of evolutionary pressures according to molecular function, biological process 
and cellular distribution. 
The data generated by various analyses served to guide the ancestral 
reconstruction of TRIM5α a potent antiviral host factor. The resurrected TRIM5α from 
the common ancestor of Old world monkeys was effective against HIV-1 and the 
recent resurrected hominoid variants were more effective against other retrovirus. 
Thus, as the result of trade-offs in the ability to restrict different retrovirus, human 
might have been exposed to HIV-1 at a time when TRIM5α lacked the appropriate 
specific restriction activity. 
The application of evolutionary and comparative genetic tools should be 
considered for the systematical assessment of host proteins relevant in viral 
pathogenesis, and to guide biological and functional studies. 
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Résumé 
 
La population mondiale est confrontée depuis le début du vingtième siècle au 
virus de l'immunodéficience humaine 1 (VIH-1). Ce virus a un taux de mutation 
particulièrement élevé, il peut donc s’évader et s’adapter très efficacement à son 
hôte. Les organismes évolutivement le plus proches de l’homme les primates non-
humains sont moins susceptibles au VIH-1. De façon générale, les primates 
répondent différemment aux rétrovirus. Cette spécificité entre espèces doit résider 
dans les différences génétiques entre primates. Dans cette étude nous avons 
appliqué des techniques d’évolution et de génétique comparative pour caractériser le 
modèle évolutif des déterminants cellulaires impliqués dans la pathogenèse du VIH-
1. L’étude de l’évolution des gènes, codant pour des protéines impliquées dans la 
restriction ou la pathogenèse du VIH-1, aidera à la compréhension des bases 
génétiques ayant récemment rendu l’homme susceptible. 
 Pour les analyses de génétique comparative, nous avons constitué une 
collection d’ADN et d’ARN de primates dans le but d’obtenir des nouvelles 
séquences de gènes orthologues. Récemment deux nouveaux génomes complets 
ont été publiés (l’orang-outan du Bornéo et Marmoset commun) en plus des trois 
génomes déjà disponibles (humain, chimpanzé, macaque rhésus). Ceci a permis 
d’améliorer considérablement étendue de l’analyse. Pour détecter l’adaptation 
moléculaire nous avons analysé les séquences à l’aide de méthodes 
phylogénétiques et statistiques. 
 Nous avons identifié différentes pressions de sélection agissant sur les 
protéines impliquées dans la pathogenèse du VIH-1. Des protéines avec des 
propriétés de restriction du VIH-1 dans les primates non-humains présentent un taux 
particulièrement haut de remplacement d’acides aminés (sélection positive). En 
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particulier dans les régions d’interaction avec les protéines virales. Ces régions 
incluent des acides aminés clé pour l’activité de restriction. Les protéines 
appartenant à l’immunité inné présentent un modèle d’évolution de conservation 
(sélection purifiante) mais avec des traces de "relaxation" comparé au profil général 
de sélection purifiante du génome des primates. Une analyse à grande échelle a 
permis de classifier les modèles de pression évolutive selon leur fonction 
moléculaire, processus biologique et distribution cellulaire. 
 Les données générées par les différentes analyses ont permis la 
reconstruction ancestrale de TRIM5α, un puissant facteur antiretroviral. Le TRIM5α 
ressuscité, correspondant à l’ancêtre commun entre les grands singes et les groupe 
des catarrhiniens, est efficace contre le VIH-1 moderne. Les TRIM5α ressuscités 
plus récents, correspondant aux ancêtres des grands singes, sont plus efficaces 
contre d’autres rétrovirus. Ainsi, trouver un compromis dans la capacité de 
restreindre différents rétrovirus, l’homme aurait été exposé au VIH-1 à une période 
où TRIM5α manquait d’activité de restriction spécifique contre celui-ci. 
 L’application de techniques d’évolution et de génétique comparative devraient 
être considérées pour l’évaluation systématique de protéines impliquées dans la 
pathogenèse virale, ainsi que pour guider des études biologiques et fonctionnelles. 
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1.1 Introduction 
 
Human and non human primates share genomes with high degree of similarity. 
However, conspicuous differences exist in how these species respond to pathogens, 
including retroviruses. The study of the evolution of genes coding for primate proteins 
participating to the restriction or pathogenesis of retroviruses may help understanding 
the genetic basis of human susceptibility to infection. Furthermore, this information 
may be used as a tool to elucidate aspects of Virus-Host co-evolution. 
 
1.2 Virus-Host Co-evolution, the Red queen effect 
 
Viruses are dependent of the host cellular machinery for replication. During this 
cohabitation, the virus may improve and adapt to the host environment, and at the 
same time the host may enhance its defences against the invading pathogen. Co-
evolution is the result of mutual influence between virus and host. This is commonly 
referred as the “Red queen effect” 1. The term is taken from Lewis Carroll's “Through 
the Looking Glass” book 2. The Red Queen says, "It takes all the running you can do, 
to keep in the same place". In scientific terms, this means that in an evolutionary 
system, continuing development is needed just to maintain its fitness relative to the 
system it is co-evolving with. At molecular level we observe changes in the genetic 
composition of the host in response to a genetic adaptation of the virus. 
 
1.2.1 The host: primate classification 
 
During millions of years primates have been natural host and reservoirs of a number 
of different retroviruses, including simian immunodeficiency virus (SIV), simian type D 
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retrovirus (SRV), simian T-cell lymphotropic virus (STLV), and simian foamy virus 
(SFV). SIV infections of more than twenty primates species have thus far been 
identified and confirmed by molecular analysis 3. The close phylogenetic relationship 
between humans and non-human primates increases the potential for cross-species 
transmission of these retroviral agents. This is the case of Human immunodeficiency 
viruses types 1 and 2 (HIV-1, HIV-2) which originated from cross-species 
transmission of closely related viruses of chimpanzees and sooty mangabeys, 
respectively 3. Thus, primates have undergone several episodes of retroviral 
infection, adaptation and cross-species transmission. This leads to footprints at the 
molecular level in the form of genetic variation among primate orthologous genes due 
to the differences on susceptibility to retrovirus infection and diseases. Primates 
provide a genetic evolution time window of more than 40 mys 4, sufficient to observe 
important genetic modifications. Analysis of a large number of primate sequences, 
relatively close in evolution time, allows a detailed analysis of genetic adaptation. 
 
Primates can be classified in four main groups: great apes (including humans), 
gibbons, monkeys and prosimians (Figure 1). Informally, monkeys are divided in two 
groups, the Old World and New World monkeys. This denomination reflects their 
geographical distribution. Old World species are from Asia and Africa, whereas New 
World species are from Central and South America. 
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Figure 1: Primate classification. Phylogenetic tree of primates used in this work. 
Approximate divergence times in millions of years (mya) are shown. 
 
1.2.2 The virus: HIV-1 
 
The Human Immunodeficiency Virus 1 (HIV-1) 5 is a lentivirus belonging to the 
retrovirus family. It is an enveloped virus possessing a RNA genome that replicates 
via a DNA intermediate. The following steps occur when the retrovirus encounters 
the cell: first, the virus enters the cell by fusing with the cellular membrane, taking 
advantage of receptor and co-receptor host proteins, that otherwise play important 
roles in immunity and inflammation. Then, the viral genetic material is delivered into 
the cytoplasm in the form of a nucleoprotein core. The viral RNA genome is copied 
into DNA by the enzyme reverse transcriptase, transported to the cell nucleus, and 
integrated in the host genome via the activity of an integrase. The proviral HIV-1 DNA 
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is transcribed into viral mRNAs, which are processed and exported to the cytoplasm. 
Finally, viral products are transported to budding sites where virions are assembled 
together with viral RNA producing new virions. 
 
Different retroviruses may have exerted selective pressures on host genes for 
millions of years. HIV-1 is a recent human pathogen, dating around 1931 6, with  a 
new report proposing a more recent date, between 1902 and 1921 7. The extensive 
genetic variation observed is this virus makes HIV-1 one of the fastest evolving of all 
organisms. The mutation rate is 3 x 10-5 par base per replication cycle in a genome of 
104 base pairs 8. It has a generation time of ~2.6 days and produces ~1011 new 
virions each day 9. Moreover the frequent recombination and natural selection further 
elevate its rate of evolutionary change. 
 
1.3 Evolutionary and comparative genetics 
 
The majority of the work presented in this thesis is based in the field of Evolutionary 
genetics. This is the broad field of studies that resulted from the integration of 
genetics and evolutionary processes. The aim is to describe how the evolutionary 
forces influence genetic variation. To identify genetic variation we use comparative 
genetics (comparing the same gene in different primate species to define the 
selection pressures exerted on it). 
 
1.4 Evolution: The nature of adaptation and selection 
 
The two main evolutionary forces exerted on DNA sequences are natural selection 
and neutral evolution. 
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Natural selection is the process by which favorable traits that are heritable become 
more common in successive generations of a population of reproducing organisms, 
and unfavorable traits that are heritable become less common. Thus natural selection 
operates by different ways: 
 
o Positive or directional selection also know as positive Darwinian 
selection, increases the frequency of a beneficial mutation. In 
evolutionary terms, there is fixation of amino acid replacements at 
protein level. 
 
o Purifying or stabilizing selection also know as negative selection 
maintains a common trait in the population by decreasing the 
frequency of harmful mutations and weeding them out of the 
population. There is maintenance of conserved amino acids over long 
periods. 
 
o Balancing selection maintains genetic polymorphisms (or multiple 
alleles) within a population. This is the situation in which natural 
selection within a population is able to maintain stable frequencies of 
two or more phenotypic forms. 
 
In neutral evolution, mutations that do not affect functionality are called neutral 
substitutions and their accumulation is not affected by natural selection. A large 
number of evolutionary changes are the result of the fixation of neutral mutations that 
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do not have effects on the fitness of an organism. An independent process from 
natural selection that produces random changes in the frequency of traits in a 
population is the Genetic drift. This phenomenon results from the role that chance 
plays in determining whether a given trait will be passed on as individuals survive 
and reproduce. A population bottleneck is an evolutionary event in which a 
significant percentage of a population or species is killed or otherwise prevented from 
reproducing. Population bottlenecks increase genetic drift, as the rate of drift is 
inversely proportional to the population size. 
 
In this work we focus on two forms of natural selection driving primate genome 
evolution. The degree of positive and purifying selection acting on primate genes 
could indicate their evolutionary pattern. Constrains imposed by protein folding and 
function result in domains under purifying selection. Regions under positive selection 
could reveal regions of protein-virus interaction due to the red queen effect. In this 
particular case these replacements could confer an advantage to the host by allowing 
escape from viral pressure. 
 
1.5 Methods for detecting selection: the KA/KS ratio 
 
To analyse the nature of adaptation and selection (positive, purifying or 
neutral) in different categories of host genes, Goldman and Yang developed a 
method to estimate the nonsynonymous and synonymous substitutions rates under 
realistic evolutionary models 10. Comparison of orthologous genes sequences among 
primate species identifies nucleic acid changes in codons. Changes are synonymous 
(silent) when the encoded amino acid remains the same due to redundancy in the 
genetic code. A nonsynonymous change leads to amino acid replacement. 
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Two other major features of DNA sequence evolution are implemented in this 
method. First, the transition/transversion rate of the nucleic acid changes, where 
transition refers to a mutation changing a purine to another purine (A  G) or a 
pyrimidine to another pyrimidine (T  C) and transversion refers to the substitution of 
a purine for a pyrimidine or vice versa. Secondly, it accounts for codon-using bias, 
because different organisms show particular preferences for one of the several 
codons that encode a given amino acid. 
 
The above information allows estimation of the KA/KS ratio (also called dN/dS or ω), 
which is the number of non-synonymous substitutions per nonsynonymous site (KA) 
divided by the number of synonymous substitutions per synonymous site (KS). 
Simplistically, a value of KA/KS <1 reflects purifying selection (deleterious mutations 
are eliminated), a value of KA/KS =1 reflects neutral evolution (the protein is not under 
selection), and a value of KA/KS >1 reflects positive selection (there is fixation of 
amino acid replacements). This method provides an overview of coding sequence 
evolution, estimating the number of nonsynonymous (KA) over synonymous (KS) 
substitutions per site (averaged over the entire sequence) for each branch of the 
primates tree based on the accepted primate phylogeny 4. 
 
The maximum likelihood (ML) method calculates KA and KS values among different 
sequences using explicit models of codon substitution 11 (Box 1). Parameters in the 
model (sequence divergence t, transition/transversion rate ĸ and the KA/KS ratio) are 
estimated from the data by ML, and are used to calculate KA and KS. 
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Box 1. A model of codon substitution
The codon is considered the unit of evolution. The substitution rate from 
codons i to j (i ≠ j) is given as:
Parameter k is the transition/transversion rate ratio, πj is the equilibrium 
frequency of codon j and ω (= KA/KS) measures the selective pressure on 
the protein. Given the rate matrix Q={qij}, the transition probability matrix 
over time t is calculated as:
P(t)= {pij(t)} = eQt
Where pij(t) is the probability that codon i becomes codon j after t. 
Likelihood calculation on a phylogeny involves summing over all possible 
codons in extinct ancestors (internal nodes of the tree)
qij =
0, if i and j differ at more than one position,
πj , for synonymous transversion,
kπj , for synonymous transition,
ωπj , for nonsynonymous transversion,
ωkπj , for nonsynonymous transition.
 
 
1.6 Methods for detecting amino acid sites under positive selection 
 
Analysis of a gene averages the KA/KS ratio across all sites and positive selection is 
detected only if that average is >1. There is the potential for a loss of information 
because sites under strong purifying selection may bring the KA/KS average value 
below one, even if a limited number of sites are under strong positive selection. To 
detect such sites in a likelihood model, the standard approach is to use a statistical 
distribution to describe the variation of KA/KS among sites. This assumes several 
classes of sites in the protein with different KA/KS (>1 positive selection; 1< purifying 
selection; =1 neutral evolution). Testing of sites under positive selection involves two 
major steps. First, a likelihood-ratio test compares a model that does not allow for 
sites where KA/KS>1 with a more general model that does. Secondly, empirical 
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Bayes methods identify positively selected sites when they exist. Sites having a 
posterior probability (Post prob. >0.95) are estimated to be under positive selection. 
 
The models are: The null model, M1a (neutral), assumes a class of conserved sites 
with KA/KS=0 (purifying selection) and another class of neutral sites with KA/KS=1. 
The alternative model, M2a (positive selection), adds a third class of sites with KA/KS 
estimated from the data. If M2a fits the data significantly better than M1a and the 
estimated KA/KS ratio for the third class in M2a is >1, then some sites are under 
positive selection. Estimating whether the model M2a fits the data significantly better 
than M1a uses the likelihood ratio test. 
 
Empirical Bayes methods uses empirical data to evaluate the conditional 
probability distributions that arise from Bayes' theorem. This method estimates the 
probability of certain site, given the data at the site, to be under neutral, purifying or 
positive selection. 
 
Likelihood ratio test (LTR) evaluates whether the increase in likelihood obtained by 
adding parameters (=degrees of freedom) to a model is significant. M1a and M2a are 
two nested models: M1a (p parameters) is a special instance of M2a (p+n 
parameters), and L1 and L2 the maximum likelihoods under M1a and M2a, 
respectively. Twice the log-likelihood ratio is asymptotically χ2 (Chi square) 
distributed (n degrees of freedom) under M1a. The present work uses two (n=2) 
degrees of freedom as suggested by Yang et al. (2005) 12 for the M1a-M2a model. 
 
The formula:  2 [ln(L1) – ln(L2)] ~ χ2 (2 degrees of freedom) 
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1.7 Molecular adaptation, consequences of the red queen effect  
 
 
While different retroviruses naturally infect primates, these hosts rarely develop an 
immunodeficiency syndrome (AIDS). AIDS is characterized by decreasing CD4+ T 
cells, increased levels of T-cell immune activation, and activation-induced cell death. 
Thus, the infected primate species represents a natural reservoir of SIVs. Primates 
may however experience severe infection after exposure to a virus whose natural 
host is another primate species. They differ in their handling of related retroviruses. 
These differences include resistance to infection (for example, differences in the 
susceptibility of primate cells to various retrovirus 13,14), the satisfactory control of 
viral replication when infected (for example, in most experimentally infected 
chimpanzees, HIV-1 replicates poorly) 15, and the occurrence of infections that are 
characterized by high-level replication without the hallmarks of disease progression 
(for example, in sooty mangabey and African green monkeys) 16.Thus, there are 
different host defense mechanisms responsible for differences on susceptibility to 
retrovirus infections. These mechanisms are present in all primates but with genetic 
differences. Differences responsible for the various virus restriction capacities might 
be explained by primate lineage-specific pandemics that shape and redirect the 
different antiviral defense mechanisms. This is the consequence of the red queen 
effect, where the host adapts its antiviral defense mechanisms against a retroviral 
element which evolves at the same time to avoid host defense. Assuring the control 
of a specific retrovirus may increase susceptibility to a second retrovirus. The 
constant selective pressures exerted on host proteins implicated in viral control may 
lead to signatures of rapid evolution, as well as regions containing sites under 
positive selection due to protein-virus interaction. 
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1.8 Factors encounter by HIV-1 in the host cell 
 
 
1.8.1 Description of the host proteins chosen for the detailed analysis 
 
A number of proteins will be assessed in detail in this thesis. Two proteins have a 
specific anti-HIV restriction activity, TRIM5α and APOBEC3G. One protein PML was 
also reported to participate in HIV-1 restriction, and Cyclophilin A participates in HIV-
1 pathogenesis. The DC-SIGN family of proteins include surface receptors that plays 
an important role in the recognition of a vast panel of pathogens, including HIV-1. Toll 
like receptors are a superfamily of receptors responsible of the recognition of 
molecular motifs from pathogens. 
 
1.8.1.1 TRIM5α and PML 
 
Tripartite motif-containing protein 5 alpha (TRIM5α) and Promyelocytic leukemia 
(PML) also called TRIM19 belong to the large TRIM protein family 17. They contain a 
RING domain, one (TRIM5α) or two (TRIM19) B-boxes domains and a predicted 
coiled-coil region followed by a C-terminal domain. In TRIM5α, the C-terminal domain 
it is a B30.2 domain 18 whereas in TRIM19 it’s a EXOIII domain (exonuclease domain 
in DNA-polymerase alpha and epsilon chain, ribonuclease T and other 
exonucleases). 
 
TRIM5α it’s a cytoplasmic restriction factor implicated in the early steps of retroviral 
replication. This protein was identified from a rhesus macaque library screened for 
simian factors restricting HIV-1 replication upon transfer into permissive human cells 
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13. Rhesus TRIM5α restricts HIV-1 but the human TRIM5α does not. The mechanism 
by which TRIM5α restricts HIV-1 is not yet well understood but it is mediated by the 
B30.2 domain through a direct interaction with the viral capsid 19-22. A recent report 
indicates that TRIM5α is autoubiquitinylated within cells, and rapidly processed by 
the proteasome in a RING domain-dependent way 23. If TRIM5α encounters 
incoming sensitive retroviral cores, the complex is recruited to the proteasome and 
destroyed before initiation of the reverse transcription (Figure 2.1). 
 
PML is implicated in different cell functions, including apoptosis, transcriptional 
regulation, senescence, cell proliferation and signal transduction. PML localizes in 
nucleoplasm and in discrete subnuclear matrix associated compartments known as 
nuclear bodies, where it represents a main constituent. Recently PML has been also 
associated with antiviral activity in cooperation with type I Interferons. 
Overexpression of PML confers resistance to infection by vesicular stomatitis virus 
(VSV) and influenza A virus 24. PML has also been reported to be active against 
retroviruses (HIV, murine leukaemia virus (MLV) and human foamy virus (HFV)). One 
proposed mechanism implicates transient cytoplasmatic export of PML and its 
subsequent recruitment by the incoming retroviral preintegration complexes (PICs), 
that inhibits HIV replication (Figure 2.2) 25. The second proposed mechanism 
implicates the viral protein Tat (transactivator of the transcription) responsible of a 
correct viral mRNAs transcription of HFV; PML prevents its binding to the viral mRNA 
(Figure 2.3) 26. Interestingly, some viruses for which the replicative cycle is inhibited 
by PML have developed strategies to alter, to various extents, the integrity and 
localization of nuclear bodies-associated PML. However, how PML interferes with so 
many viruses with widely varying replication strategies is still unclear. 
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1.8.1.2 APOBEC3G 
 
The Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3G 
(APOBEC3G) is an endogenous inhibitor of HIV-1 replication 27,28. It belongs to the 
APOBEC superfamily proteins which plays an important role in innate anti-viral 
immunity. APOBEC3G antiretroviral activity is associated with the hypermutation of 
viral DNA through cytidine deamination. APOBEC3G is incorporated into HIV-1 
particles in the producer cell, and during reverse transcription deaminates cytosine 
bases to uracil in the negative-sense DNA strand, resulting in G to A hypermutations 
in the complementary positive sense DNA strand. This hypermutation renders the 
viral cDNA vulnerable to degradation by nucleases. Those cDNA that manages to 
integrate into the host genome carries multiple mutations that likely result in aberrant 
viral products 29 (Figures 2.4, 2.5, 2.6). HIV-1 and other retroviruses possess the viral 
infectivity factor (Vif) protein 30 (Figure 2.7). To induce APOBEC3G degradation, Vif 
binds the cellular proteins Cul5, elonginB, elonginC, and Rbx1, to form a cullin5-
based E3 ubiquitin ligase complex that leads to polyubiquitination and ultimately to 
proteasomal degradation of APOBEC3G 31. The human APOBEC3G fails to restrict 
HIV-1 due to the degradation imposed by the HIV-1 Vif. In contrast, a number of 
primates APOBEC3G orthologs display activity against HIV-1 14,32,33. 
 
1.8.1.3 Cyclophilin A 
 
The role of peptidylprolyl isomerase A (Cyclophilin A, CypA) in HIV replication has 
been investigated in detail after discovering in a yeast two-hybrid screen that the 
CypA binds the HIV-1 capsid 34. CypA performs cis/trans isomerisation of proline 
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peptide bonds in sensitive proteins in the cell cytoplasm. CypA interacts with viral 
protein gag in infected cells leading to its recruitment into nascent HIV-1 virions 35 
and also with incoming HIV-1 cores in newly infected cells (Figure 2). In humans, 
CypA promotes HIV-1 infectivity in target cells by a mechanism that does not require 
CypA incorporation into virions 36. However the exact mechanism of action remains 
unclear. CypA appears to prevent the action of restriction factors by altering HIV-1 
capsid conformation in a manner that makes it less sensitive to their inhibitory effect. 
In Old World monkey cells, CypA decreases HIV-1 infectivity, but only in the 
presence of TRIM5α 37. In the owl monkey, a New World monkey, a CypA 
pseudogene has been inserted into the TRIM5α coding region, replacing the B30.2 
domain with CypA and leading to a molecule called TRIMCyp 38,39. This restriction 
factor strongly restricts HIV-1 by the recruitment of the incoming viral capsid to the 
TRIM5α domain facilitated by interaction between the CypA domain and the viral 
capsid 40. Recently studies in three different old world monkeys (macaques) identified 
TRIMCyp chimeras that had arisen independently from that found in owl monkeys. 
None restricts HIV-1 41,42. Thus, CypA might have a important role in the host 
immunity, that differs among different primate species 43. 
 26
 
TRIM5α
Proteasome
degradation
TRIM5α
Peptides
Core 
entry
X No reverse     
transcription
NUCLEUS
Nuclease
HIV
INFECTED  CELL
PRODUCER CELL
Normal  
infection
1
CypA
incorporation 
into HIV virions
8
9
Recruitment of 
more CypA
cis/trans 
isomerisation of 
the viral capsid
10 HIV restriction or infection
Reverse transcription
Deamination
Mutated dsDNA
Mutated dsDNA
integration
Transcription of 
aberrant viral products
Vif
4
6
7
Vif
PML X No virus 
integration ?? 
PML X No virus replication ?? 
NB nuclear bodies
Reverse transcription
Linear dsDNA
2
Vif
PML
PML
Vif + APOBEC3G 
degradation
3
5
 
Figure 2. Host cell proteins related with HIV restriction or pathogenesis. (1) After HIV-1 infection 
and before virus uncoating TRIM5α binds the viral capsid, and then the complex TRIM5α−HIV-1 core 
is degraded by the proteasome. (2-3) PML viral restriction activity remains unclear. (4) APOBEC3G is 
incorporated into HIV-1 particles in the producer cell, (5) due to cytidine deaminase activity, the viral 
mutated DNA it’s degradated by nucleases or (6) integrated in the host cell genome, resulting in 
aberrant viral products after transcription. (7) To escape APOBEC3G hypermutation activity, HIV-1 
uses Vif to prevent its incorporation in the producer cell. (8) CypA interacts with gag in the producer 
cells leading to its recruitment into nascent HIV-1 virions. (9) More CypA is recruited by the viral core 
in the infected cell. (10) In human cells the interaction between HIV-1 and CypA is important for 
maximal infection. In Old World monkey cells CypA decreases HIV-1 infectivity. 
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1.8.1.4 DC-SIGN family 
 
The DC-SIGN family of proteins include the dendritic-cell specific ICAM-grabbing 
non-integrin (DC-SIGN) and the related proteins liver/lymph node “L”-SIGN (L-SIGN 
also called DC-SIGNR), and CD209 antigen like protein 2 (CD209L2). These proteins 
are C-type lectin receptors with roles as cell adhesion receptors and in innate 
immunity as pathogen receptors 44,45. DC-SIGN and L-SIGN recognize a vast range 
of bacteria, mycobacteria, parasites and viruses, including HIV (Figure 3. Panel 1). 
Dendritric Cells (DCs) are thought to be among the first cells infected by HIV-1 on the 
genital mucosa. Infected DCs migrate to lymph nodes where they transfer viruses to 
T cells. HIV-1 utilizes DCs as Trojan horses to spread the virus to the lymph nodes 
(Figure 3. Panel 2). DC-SIGN and L-SIGN function depends on a carbohydrate-
recognition domain separated from a particular transmembrane region by a neck 
region made up of multiple 23 amino acid repeats. These proteins are expressed in a 
tissue-specific manner. DC-SIGN is expressed on phagocytic cells such as dendritic 
cells and macrophages, while L-SIGN expression is restricted to lymph node sinus 
endothelia and hepatic sinusoidal endothelium. The third homologue, CD209L2 is 
absent in humans but present in other primates. In the Rhesus macaque, CD209L2 
has been identified in liver, spleen, lymph node, heart, and skin 46. 
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Figure 3. Mechanism of dendritic cell mediated HIV transmission and migration to 
lymphoid tissues. Panel 1. There are two types of the dendritic cell (DC)-mediated 
HIV-1 transmission to CD4+ cells in trans-infection. (A) First, by the infectious 
synapse, where the DC-specific intercellular adhesion molecule 3 (ICAM-3) 
participates in the formation of the infectious synapse. (B) Secondly, by HIV-1-
associated exosomes. Endocytosed HIV-1 gain access to endosomal multivesicular 
bodies, enabling the release of HIV-1 associated with exosomes. Then, exosome-
associated HIV-1 virions enter the CD4+ cells through membrane binding and fusion. 
(C) Direct HIV-1 infection of DCs by cis-infection. Panel 2. DCs capture HIV-1 that 
enter peripheral tissue as the mucosa, and migrate to lymphoid tissues facilitating 
HIV-1 particle transport, where the infection of T cells occurs in trans. (D) Interaction 
between DC-SIGN and ICAM-2 supports DCs tethering and rolling in endothelium. At 
the same time the HIV-1-infected DCs migrates to the lymphoid tissue. (E) L-SIGN is 
able to capture HIV-1 and bind ICAM-3 for in-trans infection of T cells with similar 
efficiency as DC-SIGN. Thus L-SIGN enhance the HIV-1 presentation to CD4+ T 
cells in the lymphoid tissues. 
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1.8.1.5 Toll like receptors 
 
Toll-like receptors (TLRs) are a protein superfamily participating in the innate immune 
response against pathogens 47. They are pattern recognition receptors (PRRs) that 
recognize specific pathogen-associated molecular patterns (PAMPs, conserved 
molecular patterns of pathogen structures). TLRs are located at the cell surface (TLR 
1, 2, 4, 5, 6 and 10) or intracellularly (TLR 3, 7, 8, 9). Signalling through TLRs results 
in a type-1 interferon response and/or the production of pro-inflammatory cytokines. 
The first piece of evidence suggesting a role for TLRs in HIV-1 pathogenesis dates 
back to 1990, when it was shown that bacterial LPS activates the viral LTR, a 
process later found to be mediated by TLR4 48. To date, at least five TLR members 
(TLR2, TLR4, TLR7, TLR8, and TLR9) have been implicated in induction of HIV-1 
expression during opportunistic co-infections 49. TLR2 and TLR9 have shown to 
induce HIV replication 50. Recently, ssRNAs from HIV were shown to be recognized 
by TLR7 and 8 51. 
 
1.8.2 Description of the host proteins chosen for the large scale analysis 
 
The recent publication of two additional primate genomes (bornean orang-utan and 
common marmoset) allows the larger scale analysis of evolutionary pressures in the 
primate lineages. In a large scale analysis, we studied the evolution pattern of the 
majority of the cellular host factors implicated in the viral cell cycle and in 
pathogenesis (137 genes). HIV-1 usurps the host cellular machinery at multiple steps 
to infect and complete a productive cycle. Host factors modulate the viral entry, the 
post-entry events and late steps of viral replication. An increasing number of genes 
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and proteins have been identified over the years, mostly through functional and cell 
biology studies 52,53, eg. the receptors CD4 and CCR5. New genes have now been 
identified through large scale siRNA screens as ”host dependency factors” 54,55. 
Progress in understanding of innate immunity and intrinsic cellular defence against 
retroviruses have also generated a series of host factors for analysis 56. Many of 
these have been evaluated for genetic polymosphism that could modulate the 
individual susceptibility to disease. Gene name, Molecular function, cellular location, 
possible interaction between the host factors and HIV-1 proteins are listed in the 
Supplementary table S1 in chapter 4.3, page 75. 
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Chapter 2. Hypothesis and aims 
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Hypothesis: 
 
• Primates and retrovirus have co-evolved during millions of years, each 
exerting mutual selective pressures. 
• Selective pressures may be identified through use of comparative genetics. 
Signatures of positive selection could reveal regions of protein-virus 
interaction, identify relevant functional amino acids in host proteins implicated 
in HIV-1 restriction or pathogenesis and in the various steps of the viral life 
cycle. 
 
The aims of the present study are: 
 
• Analyse and classify in detail the evolution pattern of fifteen proteins related to 
HIV-1 restriction or pathogenesis. For this, we need to: 
 
o Build a DNA-RNA-Cell collection that includes material from sixteen 
primate species representative of the four main primate groups. 
(Chapter 3.1) 
 
o Create a dataset of new primate sequences. 
 
• Perform a large scale evolutionary analysis of the majority of known host 
proteins involved in the HIV-1 life cycle and pathogenesis. For this, we need 
to: 
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o Use the available completed genomes of human, chimpanzee, bornean 
orang-utan, Rhesus macaque and common marmoset to identify the 
orthologous proteins (Chapter 3.3) 
 
• Classify the evolutionary pattern for each protein. (Chapter 4.1-2-3) 
• Identify “patches” of amino acids or individual amino acids under positive 
selection. (Chapter 4.1-2-3) 
 
• Localized which steps of the retroviral cell cycle have been under selective 
pressures due to ancient genetic conflicts with ancestral retrovirus. (Chapter 
4.3) 
• Use this information to direct functional analyses. (Chapter 4.4) 
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Materials and methods 
 
3.1 Primate collection 
 
DNA samples of bonobo (Pan paniscus), chimpanzee (Pan troglodytes), gorilla 
(Gorilla gorilla), bornean orang-utan (Pongo pygmaeus), nomascus (Hylobates 
leucogenys), siamang (Hylobates syndactylus) and red baboon (Papio hamadryas) 
were kindly provided by Dr. Henrik Kaessmann from the Center of Integrative 
Genomics and Dr. Robert Hammond from the Department of Ecology and evolution, 
UNIL Lausanne. In addition, RNA-DNA extraction was performed with RNeasy Mini 
Kit (Cat No.74104) and QIAamp DNA Blood Mini Kit (Cat No.51104) on cells from: lar 
gibbon (Hylobates lar) lymphoblast (MLA144 cell line); African green monkey 
(Cercopithecus [chlorocebus] aethiops) kidney fibroblast (COS-7 cell line); rhesus 
monkey (Macaca mulatta) skin fibroblast (AG07128 cell line); owl monkey (Aotus 
trivirgatus) kidney (OMK cell line); cotton-top tamarin (Saguinus Oedipus) 
lymphoblast (B95-8 cell line); common marmoset (Callithrix jacchus jacchus) cells 
from a piece of frozen liver kindly provided by Keith Mansfield and Kuei-Chin from the 
New England primate research center; golden headed lion (Leontopithecus rosalia 
chrysomelas) cells from peripheral blood kindly provided by Charles Buillard and 
Eugène Chabloz from the Zoo of Servion; ring-tailed lemur (Lemur catta) skin 
fibroblast (AG07099 cell line). 
 
3.2 Molecular analysis 
 
To obtain the coding region of the genes analysed herein, we amplified and 
sequenced the exons with primers designed for the flanking intron regions on 
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genomic DNA and the 3’ and 5’ UTR regions on cDNA, when available. The primers 
were designed based on the alignment of the three complete available genomes 
(human-chimpanzee-rhesus monkey) at this period, from the UCSC (University of 
California Santa Cruz) Genome Browser 
(http://hgdownload.cse.ucsc.edu/downloads.html). HotStarTaq Master Mix (QIAGEN) 
was used for PCR (Polymerase Chain Reaction) amplification of DNA fragments 
smaller than 1 kb, and PrimeSTART DNA polymerase (TAKARA) or PfuTurbo DNA 
Polymerase (Stratagene) for fragments larger than 1 kb to avoid errors in DNA 
amplification. PCR conditions of annealing, step cycling and extension were 
optimised for each experiment. For sequencing, BigDye Terminator V1.1 Cycle 
sequencing Kit (Applied Biosystems) was used. 
 
3.3 Orthologous genes identification in non-human primates complete 
genomes 
 
To obtain the orthologous sequences of genes in four non human primates, the last 
genome assembly (hg18) of human (Homo sapiens), (panTro2) of chimpanzee (Pan 
troglodytes), the available genome assembly of (ponAbe2, WUSTL Pongo_albelii-
2.0.2) Sumatran orang-utan (Pongo pygmaeus abeli), the genome assembly 
(rheMac2) of rhesus monkey and the the available genome assembly (calJac1, 
WUSTL Callithrix_jacchus-2.0.2) of common marmoset (Callithrix jacchus) were 
downloaded from UCSC genome browser. Human complete genome was release in 
April 2003, chimpanzee in March 2005, rhesus monkey in January 2006. Sumatran 
orang-utan and common marmoset draft assemblies were release in March and April 
2008 respectively. BlatSuite.34 version of BLAT (BLAST – Like Alignment Tool) 57 
was used with the human coding region sequence as template to retrieve homology 
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sequences from each genome with parameters “-t dnax –q dnax” (i.e. translated 
DNA). BLAT of the querying sequences in the five primates genomes was performed 
chromosome by chromosome using positive strand chain, then the homologous 
sequence with the maximum match value was taken. 
 
3.4 Evolutionary analysis 
 
Sequences were aligned using the sequence analysis tool MUSCLE (MUltiple 
Sequence Comparison by Log-Expectation) 58. Coding regions were aligned 
according to their corresponding amino acid sequences using the tranalign 
application of the EMBOSS package (European Molecular Biology Open Software 
Suite) 59. 
 
3.4.1 Branch Models 
 
To trace the evolutionary history of the genes, we analyzed their substitutional 
patterns in the framework of the accepted primate phylogeny 4 using several codon-
based maximum likelihood procedures as implemented in the codeml tool of the 
Phylogenetic Analysis by Maximum Likelihood (PAML) program package 60. To 
obtain an overview of the coding sequence evolution, we estimated the number of 
nonsynonymous (KA) over synonymous (KS) substitutions per site (averaged over the 
entire sequence) for each branch of the trees using the free-ratio model of codeml. 
 
3.4.2 Site specific models 
 
In a more detailed analysis, to identify regions containing sites under positive 
selection, we utilized models that allow for different KA/KS rates at different sites of 
the sequence, because adaptive evolution often occurs at a limited number of sites 
 41
11. We first compared a null model (“M1a”, 12,61), which assumes two site classes 
(sites under purifying selection and neutrally evolving sites), to an alternative model 
(“M2a”, 12,61), which adds a third site class that allows for sites with KA/KS > 1, using 
likelihood ratio tests 62. 
 
For additional information about materials and methods, refer to the detailed 
“Materials and methods” in the original articles (Chapter 4. Results). 
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4.1 Original article 
 
Patterns of evolution of host proteins involved in retroviral 
Pathogenesis 
 
Millan Ortiz1, Gabriela Bleiber1, Raquel Martinez1, Henrik Kaessmann*2 and Amalio 
Telenti*1 
 
Address: 1Institute of Microbiology and University Hospital, University of Lausanne, Switzerland and 2Center for Integrative 
Genomics, University of Lausanne, Lausanne, Switzerland 
 
Retrovirology 2006 Feb 7;3:1163. 
 
Comments on the article: 
This study analyzed patterns of coding sequence evolution of four genes with known 
(TRIM5α and APOBEC3G) or suspected (PML) role in virus restriction, or in viral 
pathogenesis (PPIA, encoding Cyclophilin A), in the same set of human and non-
human primate species. Detailed analysis of the four model proteins confirmed the 
previously described pattern of (i) strong positive selection on TRIM5α and multiple 
regions of conflict, and identified (ii) strong positive selection on APOBEC3G with 
better defined regions of host gene-virus co-evolution than previously reported, (iii) 
strong purifying selection for PML with absence of residues under positive selection, 
and (iv) full conservation of PPIA among primates. This suggests that PPIA and PML 
are not direct effectors of antiviral response. Together, the results presented here 
further support that an evolutionary genomics approach may be very useful for 
systematically assessing functional roles of primate host proteins potentially relevant 
in viral pathogenesis. 
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4.2 Original article 
 
The evolutionary history of the CD209 (DC-SIGN) family in human 
and non-human primates 
 
Millan Ortiz1, Henrik Kaessmann2, Mary Carrington3, Lluis Quintana-Murci4, Amalio 
Telenti1* 
1Institute of Microbiology, University of Lausanne, Lausanne, Switzerland, 2 Center of Integrative Genomics, University of 
Lausanne, Lausanne, Switzerland, 3Laboratory of Molecular Immunology, US Army Medical Research Institute of Infectious 
Diseases, Frederick, MD, USA; 4Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederich 
Inc., NCI-Frederick, Frederick, MD, USA and 5 Institute Pasteur, Human Evolutionary Genetics, CNRS, URA3012, Paris, France 
 
Genes & immunity 2008 Sep;9(6):483-92 64 
 
Comments of the article: 
CD209 family genes encode for C-lectin receptors that recognize a vast range of 
pathogens. It includes three members, DC-SIGN, L-SIGN and CD209L2. DC-SIGN 
and L-SIGN function depends on a carbohydrate-recognition domain separated from 
a transmembrane region by a neck region made up of several repeats. The 
importance of these receptors in pathogen recognition, as well as the importance of 
dendritic cells in pathogenesis of HIV-1 infection make these genes an excellent 
model system to investigate their distribution in primates in order to (i) thoroughly 
assess their evolutionary history (ii) identify amino acids under positive selection (iii) 
date the origin of gene duplication (iv) understand the evolutionary process giving 
raise to the neck repeat region. The phylogenetic tree supports a scenario where 
CD209L results from a duplication of CD209. Overall, CD209 and CD209L2 genes 
present a evolution pattern consistent with purifying selection. However, detailed 
analysis shows that L-SIGN presents a small subset of sites class under positive 
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selection, where we identifiedy three residues under positive selection. A second 
family of major innate immunity microbial sensors, namely the Toll-like receptor (TLR) 
gene family that identifies specific pathogen-associated molecular patterns (PAMPs) 
was investigated in parallel. The observed degree of purifiying selection of the Toll-
like receptor family may be expected given the need to faithfully recognize various 
pathogens motifs and the inability of pathogens to modify the specific molecular 
patterns. 
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4.3 Original article (in preparation) 
 
Evolutionary Pattern of Host Genes Involved in HIV Pathogenesis 
 
Millán Ortiz1, Nicolas Guex2, Olivier Martin2, Ioannis Xenarios2, Angela Ciuffi1, 
Amalio Telenti1* 
1Institute of Microbiology, University of Lausanne, 2Vital-IT, Swiss Institute of Bioinformatics, Lausanne, Switzerland 
 
Comments of the article: 
The recent availability of the complete genomes from five primates allows the 
analysis of genetic diversity over the last 40 million years evolution. We established a 
priority list of human candidate genes involved in the HIV-1 life cycle and 
pathogenesis based on published reports, and a control set of random genes. The 
orthologous genes were retrieved from the genome of the four non-human primates 
and we analyzed the nucleotide substitution patterns. Similar median KA/KS (~0.2) 
values were estimated for the set of candidate genes and for the controls genes. The 
genes were placed in the cellular context and in relation to the different stages of the 
HIV-1 life cycle. Genes involved in virus entry, early phase, nuclear import, 
integration, transcription nuclear export and late phases of the viral replication cycle 
were under significantly stronger purifying selection than the average across control 
genes. Genes of the innate immunity presented median values of (~0.4), and among 
these, genes of intrinsic cellular defense were under positive selection. Detailed 
analysis of genes in the upper KA/KS quintile (>0.4) by using up additional primate 
sequences allowed the identification of residues under positive selection in nine 
genes. In ten instances, the identified residues were relevant for HIV-1 biology. 
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Abstract: 
Background: The availability of the complete genomes from five primates allows the 
analysis of genetic diversity over the last 40 million years evolution. We hypothesized 
that inter-species differences in susceptibility to HIV-1 would be influenced by the 
long-range selective pressures on host genes associated with HIV-1 pathogenesis. 
Materials and Methods: We established a priority list of human genes (n=140) 
involved in the HIV-1 life cycle and pathogenesis based on published reports, and a 
control set 100 random genes. We retrieved the orthologous genes from the genome 
of the four non-human primates (Pan troglodytes, Pongo pygmaeus abeli, Macaca 
mulatta and Callithrix jacchus) downloaded from UCSC. We analyzed the nucleotide 
substitution patterns using codon-based maximum likelihood procedures as 
implemented in the PAML software. 
Results and conclusion: Similar median KA/KS value were estimated for the set of 
140 genes involved in HIV-1 pathogenesis and for 100 random controls genes; 0.19 
and 0.23, respectively. However, while genes involved in HIV-1 early and late 
replication phases had values similar to those estimated for random genes, other 
determinants of HIV-1 pathogenesis presented a different evolutionary history. 
Genes of the innate immunity had median values of 0.40, and among these, genes of 
intrinsic cellular defense had values KA/KS around or greater than 1.0 (positive 
selection). Detail assessment of thirty genes in the upper KA/KS quintile (>0.4) by 
using additional primate sequences allowed the identification of residues under 
positive selection in TRIM5a, APOBEC3H, APOBEC3G, CD4, IL4, PTPRC, GML, 
DEFB1 and L-SIGN. In ten instances, the identified residues are relevant for HIV-1 
biology. Thus, long-acting selective pressures on primate genomes may lead to 
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variation in genes influencing contemporary susceptibility to HIV-1 infection and 
disease. 
 
Introduction 
Infectious diseases are thought to be a major force driving evolution. This concept 
has been supported by several genome-wide studies that ranked genes involved in 
immunity and inflammation among those exhibiting the strongest features of positive 
selective pressure1,2,3,4. These studies used comparative genome data across 
mammals or analysed features of human population differentiation. Therefore, 
evolutionary genomic analysis could identify genes that play a role in modern 
susceptibility to infectious diseases2,5,6. 
 
Among infectious agents, retroviruses can shape the genome both through their 
contribution to the large mass of genetic material of retroviral origin, and via repetitive 
attacks by exogenous infection. By now it is well established that a number of cellular 
factors specifically target retroelemental activity – of endogenous retroviruses, as 
well as incoming infection7,8,9,10. Modern susceptibility to lentiviruses, and in particular 
to HIV-1 and SIVs, could thus be modulated by past exposure to ancestral retroviral 
infections, leading to interspecies specificities, and within a given species, to 
interindividual differences in susceptibility to infection and disease. On the other 
hand, genetic adaptation to bottlenecks due to epidemics by non-retroviral pathogens 
may also modify modern susceptibility to HIV-1 through shared determinants of 
immune response or polymorphism in key cellular processes. 
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The evolutionary pattern of members of two families of genes involved in intrinsic 
cellular defense against retroviruses are the best examples of evolutionary pressures 
exerted by past infections. TRIM5α, a protein that restricts retroviral infection by 
targeting decapsidation, and APOBE3G and 3F, proteins that deaminate viral RNA, 
are among the proteins under the strongest positive selective pressure in 
primates5,6,11. Detailed analyses identified patches of residues under positive 
selection pressure representing regions of direct interaction between viral proteins 
and the host antiretroviral protein. Reconstruction and functional testing of ancestral 
antiretroviral proteins or of ancient retroviruses supports evidence for a dynamic 
process of evolution of antiretroviral specificity in the primate lineages that results in 
the pattern of restriction to lentivirus and other retrovirus observed in modern 
primates12,13,14. 
 
The recent availability of human and of four non-human primate complete genomes 
facilitates the large scale analysis of evolutionary pressures on coding regions. It 
allows testing the hypothesis that genes that are under strong selection in primates 
may be particularly relevant to human susceptibility to HIV-1 disease. For this 
purpose, we conducted a systematic assessment of 140 genes involved in HIV-1 
pathogenesis and biology to characterize their pattern of evolutionary pressure, and 
to identify single residues in host proteins that are of relevance in infection. 
 
Materials and methods 
Selection of genes candidates for the analysis. We screened the literature for (i) 
genes associated with the biology of HIV-1 (reviewed in15,16,17,18 and recent 
studies10,19,10); (ii) HIV-1 dependency factors emerging from genome-wide siRNA 
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screens 21,22,23; and (iii) genes considered polymorphic and involved in HIV-1 
pathogenesis (compiled in www.hiv-pharmacogenomics.org) (Figure 1). For the 
three large siRNA screens, that included over 600 candidates, we restricted analysis 
to (i) genes identified in at least two of three screens, or to (ii) genes with single 
nucleotide polymorphisms that reached a nominal significant p value in a recent 
genome-wide association study of determinants of susceptibility to HIV-124. 
 
Orthologous genes identification in non-human primates. To obtain the 
orthologous sequences of candidate and control genes in the four non-human 
primates, the last genome assembly (hg18) of human (Homo sapiens), (panTro2) of 
chimpanzee (Pan troglodytes), the available genome assembly of (ponAbe2, WUSTL 
Pongo_albelii-2.0.2) Sumatran orangutan (Pongo pygmaeus abeli), the genome 
assembly (rheMac2) of rhesus monkey (Macaca mulatta) and the available genome 
assembly (calJac1, WUSTL Callithrix_jacchus-2.0.2) of common marmoset (Callithrix 
jacchus) were downloaded from UCSC genome browser. BlatSuite.34 25 was used 
with the human coding region sequence (CDSs) as template to retrieve homology 
sequences from each genome with parameters “-t dnax –q dnax” (i.e. translated 
DNA). BLAT of the querying sequences in the five primate genomes was performed 
chromosome by chromosome using positive strand chain, then the homologous 
sequence with the maximum match value was taken. 
 
Alignment of the orthologous sequences. The CDSs for the 140 candidate genes 
of the five primates were aligned using the sequence analysis tool MUSCLE 
(MUltiple Sequence Comparison by Log-Expectation)26. CDSs were aligned 
according to their corresponding amino acid sequences using the tranalign 
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application of the EMBOSS package (European Molecular Biology Open Software 
Suite)27. 
 
Primate evolutionary analysis. To trace the evolutionary history of the 140 
candidate host genes and 100 control genes (randomly selected among 23000 
human genes), we analysed their substitutional patterns in the framework of the 
accepted primate phylogeny28 using several codon-based maximum likelihood 
procedures as implemented in the codeml tool of the PAML (Phylogenetic Analysis 
by Maximum Likelihood) program package29. To obtain an overview of the coding 
sequence evolution, we estimated the number of non-synonymous (KA) over 
synonymous (KS) substitutions per site (averaged over the entire sequence) for each 
branch of the trees using the free-ratio model of codeml. In more detailed analysis, in 
certain genes, we utilized models that allow for different KA/KS rates at different sites 
of the sequences, because adaptive evolution often occurs at a limited number of 
site30. We first compared a null model (M1a31,32), which assumes two site classes 
(sites under purifying selection and neutrally evolving sites), to an alternative model 
(M2a31,32), which adds a third site class that allows for sites with KA/KS>1) using 
likelihood ratio test. We then use empirical Bayes methods to identify positively 
selected sites when they exist. Sites having a posterior probability (Post prob. >0.95) 
are estimated to be under positive selection. For this detailed analysis all the 
primates complete CDSs available in NCBI database were used. 
 
Cellular localization and classification. Genes/proteins were placed in the cellular 
context and in relation to the different stages of the HIV-1 life cycle. Molecular 
function, cellular location and possible interaction between the host factors and HIV-1 
 69
proteins (Supplementary table S1) were assigned using the available literature and 
dedicated databases (HIV-1 Human Protein Interaction Database from NCBI, 
http://www.ncbi.nlm.nih.gov/RefSeq/HIVInteractions; Ingenuity Pathways Analysis 
Database (Ingenuity® Systems, http://www.ingenuity.com), Gene Ontology Database, 
http://www.geneontology.org/). 
 
Results 
BLAT and alignment efficiency. CDSs of human candidate genes (n=140) were 
used as BLAT queries against the four non-human primate genomes. We identified 
and reconstructed all four non-human primate orthologs (558 sequences) with the 
exception of L-SIGN (also called CLEC4M), known to be absent in old and new world 
monkeys33,34. Of the 558 sequences, 338 included the entire CDS compared to the 
human sequence template. The remaining sequences contained gaps of different 
size in different primates. Gaps represented 1% to 30% of the CDS compared to the 
human reference sequence. The only exception was CCL18 in common marmoset, 
which missed 68% of the expected CDS. For the one hundred control random genes 
we identified all four non-human primates orthologs (n=400). Over the 400 
sequences, 284 included the entire CDS compared to the human sequence template. 
The remaining sequences (n=116), contained gaps representing 1% to 10% of CDS. 
Gap sequences could be due to the incomplete genome assembly or represent an 
actual event of deletion/insertion. There is debate about the best handling of short 
deletions or insertions in the analysis of sequence evolution35. In this study, 
insertions and deletions were defined from the consensus sequence. Positions in 
gaps were coded as “?” to be interpreted as undetermined nucleotide by the PAML 
program. Insertions were removed from analysis. 
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KA/KS analysis. The KA/KS median value for the one hundred random control genes 
was 0.19 (purifying selection). The KA/KS median value for candidate genes involved 
in HIV-1 pathogenesis was 0.23. Classification of candidate genes according to 
molecular function resulted in differences in KA/KS median values among functional 
classes. Immune response genes, including the innate and intrinsic immunity had 
median values of 0.37 and 1.04; p value=0.0001 and p=0.0005, respectively, 
compared to the control genes (Figure 2). Genes involved in virus life cycle steps 
(entry, early phase, nuclear import, integration, transcription, nuclear export and late 
phase) presented median values similar or below that of control genes. These 
differences were statistically significant for genes involved in transcription (p=0.0125), 
nuclear export (p=0.0158) and late phases of the viral cycle (p<0.0001). KA and KS as 
well as the KA/KS ratio values for all genes analyzed in this work are annotated in 
Supplementary table S1. 
 
We compiled and presented data in their cellular context (Figure 3). Among 42 
genes/proteins encoding membrane receptors, plasma membrane proteins, and 
soluble molecules, we identified 16 host factors (38%) with values in the upper KA/KS 
quintile (KA/KS>0.4). The gene under strongest positive selection (KA/KS>1) is CCL11, 
encoding for eotaxin (chemokine C-C motif ligand 11), a small secreted protein 
involved in immunoregulatory and inflammatory processes. It has been suggested 
that eotaxin controls the migration of immune cells to sites of HIV-1 infection36. Other 
genes/proteins in the upper quantile of KA/KS included PTPRC (KA/KS=0.71), 
encoding CD45, a protein abundantly expressed on the surface of B- and T-cells, 
that has important functions in cell maturation and activation; CD4 (KA/KS=0.70), 
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encoding the primary receptor for SIV/HIV; and CLEC4M (KA/KS=0.61), encoding a 
C-type lectin receptor that binds HIV-1. We also found three members of the 
interferon response system (IFNAR1, KA/KS=0.62; IFNGR1, KA/KS=0.52; IFNG, 
KA/KS=0.44) in addition to interleukins, interleukin receptors and chemokines (IL1A, 
KA/KS=0.76; IL18, KA/KS=0.46; IL2RA, KA/KS=0.42; CCL7, KA/KS=0.65; CCL18, 
KA/KS=0.52). DEFB1 (KA/KS=0.58), encodes a defensin from a family of microbicidal 
and cytotoxic peptides, and MBL2 (KA/KS=0.59) encodes a mannose-binding protein 
that binds HIV-1 gp120. Other genes/proteins located in the plasma membrane in the 
upper KA/KS quantile includes GML (KA/KS=0.67), encoding a GPI-anchor protein of 
the LY6 family, recently associated with differences in cellular susceptibility to 
infection19, and Tetherin/BST2 (KA/KS=0.58), a protein that restricts HIV-1 release. It 
is downregulated from the cell surface by direct biding of HIV-1 Vpu (Viral protein 
U)10. 
 
Among 53 genes/proteins involved in molecular functions in the cytoplasm, we 
identified five host factors (9%) with values in the upper KA/KS quintile. APOBEC3H 
(KA/KS=1.25), APOBEC3G (KA/KS=1.25), TRIM5α (KA/KS=1.04 )and APOBEC3F 
(KA/KS=0.91) are known to be under positive selective pressure37,5,6,11. MAP4 
(KA/KS=0.57) was recently proposed as HIV-1 dependency factor in two siRNA large 
scale screens21,23. 
 
Among 43 genes/proteins involved in nuclear functions, most were under strong 
purifying selection, with the exception of three genes (7%) with values in the upper 
KA/KS quintile. TRIM22 (KA/KS=0.63) encodes an intrinsic immunity factor involved in 
the regulation of transcription20,38. DDX53 (KA/KS=0.50), recently proposed as HIV-1 
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dependency factor in a siRNA large scale screen brass21, is associated with viral 
mRNA processing. CDC25C (KA/KS=0.42) encodes a protein promoting cell cycle 
arrest that binds HIV-1 Vpr (Viral protein R)15,39. Functional details and association 
with HIV-1 pathogenesis of all genes/proteins are detailed in Supplementary table 
S1. 
 
Genes/Proteins with regions under positive selection. In a more detailed 
analysis, we applied different PAML statistical models (M1a and M2a) to identify 
residues under positive selection in gene products with a KA/KS values >0.4. This 
analysis includes 28 of the candidate genes mentioned before. Because the 
identification of sites under positive selection could be limited by the number of 
primate sequences, we compiled additional complete CDSs of non-human primates 
in the NCBI database (Table 1). APOBEC3H, APOBEC3G, APOBEC3F, TRIM5α, 
TRIM22 and CLEC4M/L-SIGN have been already well characterized in terms of their 
evolutionary history37,5,6,11,34. For APOBEC3H, APOBEC3G and TRIM5α the 
availability of additional sequences allowed the detection of novel sites predicted to 
be under positive selection. For five additional genes/proteins (CD4, IL4, 
PTPRC/C45, GML, DEFB1), we identified one to ten residues to be under positive 
selection (Post probs. >0.95), (Table 1). Residues N64, N77, and A80 of CD4 are 
distributed on the molecular surface at the top of domain D1 at the interface between 
CD4 and the HIV protein gp120, and between CD4 and MHC-II40. PTPRC/CD45 L33, 
N276, A277, T292, Q334, K353, F397, V454, R504 and K533 are located in the 
extracellular spacer and fibronectin domains. This protein region could be under 
positive selective pressure due to a genetic conflict between host and a pathogen, 
but there is no evidence for CD45 to bind directly to a retroviral protein although it 
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has been implicated in the binding of influenza virus41. Altered CD45 expression in 
C77G carriers influences immune function and outcome of hepatitis C infection42. A 
recent study described the promoter region of IL4 gene to be under selective 
pressure due to local adaptation to diverse pathogenic challenges43; however, IL4 
S152 is located at the C-terminus. No information is available regarding DEFB1 R61, 
or GML S107. 
 
Control genes. Two genes in the control group, IFNA8 (KA/KS=1.33) and PHYHD1 
(KA/KS=1.22) are under strong positive selection (Supplementary table S2). 
PHYHD1 encodes for hytanoyl-CoA dioxygenase domain containing 1, a molecule 
with oxidoreductase activity. PHYHD1 was described as interacting with Epstein Barr 
virus BRRF1 protein in a high-throughput yeast two-hybrid system44. BRRF1 is a 
transcription factor cooperating in the induction of the lytic form of EBV infection in 
certain cell types45. No residues were found to be under positive selection (Table 1). 
IFNA8 encodes an interferon molecule implicated in anti-viral response, although not 
reported to be specifically associated with HIV-1 pathogenesis. IFNA8 R45, a surface 
accessible residue, is predicted to be under positive selection (Table 1). 
 
Discussion: 
Human susceptibility to HIV-1 occurred at a time in evolution of the species when 
host capacity to abort, control, or resolve infection was limited. The almost-universal 
susceptibility to HIV-1 in humans stands in stark contrast to the outcome of infection 
of SIV in their natural primate hosts. Members of the TRIM and APOBEC families of 
proteins, and Tetherin/Bst2 account for differences in retroviral restriction specificity 
among primate species. The differences in pathogenesis that underlie the ability to 
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tolerate viral replication without immune damage in sooty mangabeys or African 
green monkeys, have been difficult to map to precise genes. While naturally SIV-
infected primates are thought to have gone through a long host-pathogen adaptation 
process – in contrast with the recent infection of humans with HIV-1. Thus the 
interest and the goal of the current work to assess the evolutionary profiles of 140 
candidate and confirmed genes/proteins involved in HIV-1 biology and pathogenesis. 
This is now facilitated by the possibility to search for orthologs of human genes in the 
complete genomes of four evolutionary distant primates. 
 
The choice of genes for study covers confirmed cellular factors needed for viral 
replication, as well as candidate genes that have emerged from genetic association 
studies and from three genome-wide siRNA screens. This set of genes allows the 
following observations: (i) three general groups of genes with different evolutionary 
history of their coding regions in primates (as captured by the KAKS ratio), (ii) the non 
a priori identification of residues that are candidate interaction domains with 
pathogen(s). Three general patterns of selective pressure in coding regions emerged 
from the analysis of 40 million years of primate evolution.  
 
First, cellular genes proven (or proposed) involved in early phase of the viral cycle, 
nuclear import, integration, transcription, nuclear export and late phase are under 
strong purifying selection – with most values below the genome-wide average of 
KAKS = 0.2. Thus, it can be argued that differences in susceptibility to retroviruses 
among primates are less likely to be coded (and coding) in those genes. It could also 
be argued that the available mutational space available for mutation and 
polymorphisms in modern humans may be limited. This consideration may be of 
 75
interest when planning re-sequencing of these genes for the purpose of identifying 
the genetic basis for differential HIV-1 susceptibility and disease evolution in humans.  
 
Second, cytokines, chemokines, and other soluble mediators and receptors of the 
innate immunity have a distinctive pattern of evolution of coding regions with average 
KAKS  values approaching a ratio of 0.4. This values can be referred to as relaxing of 
purifying selection, balancing selection, or though of as evidence of positive selection 
acting of domains of these proteins. In contrast with the first set of genes, the 
available mutational space may be larger, and diversification of these mediators of 
the innate immunity might have functional consequences – including in the 
pathogenesis of retroviral infection.  
 
Third, the current study confirms the role of positive selection in shaping intrinsic 
cellular defense against retroviruses – including the recently described pattern of 
Tetherin/Bst2. It is apparent from this analysis that a representative set of 5 primate 
genomes can capture the signal of strong positive selection in those genes, thus 
highlighting the need to study in detail other uncharacterized genes that present 
similar KAKS ratios for a possible role in anti-retroviral defense. 
 
Next, we used approaches to allow for different KA/KS rates at different sites of the 
sequences, because adaptive evolution often occurs at a limited number of sites30. 
This type of analysis can provide precious information on residues and pathogen-
interacting domains. The accuracy of the analysis increases with increasing numbers 
of primate sequences. Sites predicted under selective pressure could be thus 
identified in 9 proteins. It confirmed and extended the number of residues under 
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selective pressure in the intrinsic defense proteins TRIM5α, APOBEC3H and 
APOBEC3G. In addition, it identified three residues, N64, N77, and A80, of receptor 
CD4. Residues N64 and N77 appear to be involved directly in binding of gp120, 
residue A80 may affect gp120 binding indirectly46. It is possible that the residues 
under positive selective pressure identified in IL4, PTPRC, GML, DEFB1, and 
CLEC4M/L-SIGN are relevant to host-pathogen interactions. 
 
In conclusion, this work represents a large-scale approach to the characterization of 
the evolutionary history of genes involved in retroviral pathogenesis during primate 
evolution. This is an effort that needs to be followed by the analysis at human 
genome level, with the progressive precision provided by additional complete 
genomes of primates and prosimians. The outcome of such studies should guide 
functional analysis of candidate genes, and of residues that may identify interaction 
domains with pathogens. 
 
Acknowledgements 
This work was funded by the Swiss National Science Foundation and by a grant from 
the academic foundation Infectigen. 
 
 77
 
Figure 1. Number of candidate genes involved in the HIV life cycle and pathogenesis 
selected for analysis. 
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Figure 2. KA/KS values of candidates and control genes. Each point represents 
the KA/KS ratio value for one gene. Genes with KA/KS>1 are consider under positive 
selection. Candidates genes are divided in different categories according to their 
function in relation with the HIV-1 cell cycle. The bar represents median values of the 
KA/KS ratios of the different genes groups. 
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Figure 3. Subcellular location and degree of selective pressure of the candidate 
genes. Host factors are localized in the cell using the different stages of the HIV-1 
life cycle as a framework (blue circles). The subcellular location, function and 
possible direct interaction with HIV-1 elements was determined using multiple 
databases and the literature. The degree of molecular evolution is classified in KA/KS 
quantiles: 0 to 0.1151 (grey), 0.1152 to 0.2242 (yellow), 0.2377 to 0.3931 (bisque), 
0.4055 to 0.9271 (orange), and higher than one (red). Solid lines correspond to direct 
protein-protein binding. Dashed lines correspond to ligand-receptor interactions. 
Selected HIV-1 proteins (Gag, gp120, IN, Nef, Rev, Tat, Vif, Vpr, Vpu) are depicted in 
black. Endoplasmic reticulum (ER). 
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Table 1. Test for positive selection in codons of candidate genes. 
 
 
 
(1) Number of primate sequences available for analysis. 
(2) KA/KS branch values averaged over the entire tree (free ratio model). 
(3) The KA/KS value for the additional site class and percentage of residues under 
positive selection. 
(4) Sites under positive selection by Bayes Empirical Bayes analysis. Posterior 
probability >0.95 (underlined if > 0.99). The numbering is based on the human 
sequence. 
Gene name Gene ID Primates (1) KA/KS (2) KA/KS>1(3) p-value Sites with KA/KS > 1 (4) 
Candidates genes      
TRIM5α 85363 31 1.209 
 
4.49 (17.99%) 1.67E-35 
 
V7, Q107, Q175, L182, T215, 
L228, Q272, C310, K324, P325, 
I328, G330, R332, R335, Q337, 
T338, F339, V340, N343, P381, 
C385, K389, E405, V408, F418, 
P421, V423, G483 
APOBEC3H 164668 14 1.204 3.79 (31.82%) 8.20E-09 
 
R20, R21, C53, W90, Y113, 
K117, P118, Q119, C127, G128, 
P139, A142, E152, N169, A172 
APOBEC3G 60489 16 1.144 3.98 (22.81%) 2.19E-34 
 
E61, R69, H72, K76, R78, R82, 
E85, T98, K99, T101, R102, 
D103, T106, V120, D128, P129, 
E133, S137, K141, R142, R146, 
D155, Q168, R169, I187, R213, 
D274, D276, E330, K344 
CD4 920 12 0.769 3.29 (15.97%) 3.34E-05 N64, N77, A80 
IL4 3565 10 0.765 20.22 (1.26%) 1.36E-02 S152 
PTPRC 5788 5 0.719 8.86 (5.54%) 1.60E-17 L33, N276, A277, T292, Q334, K353, F397, V454, R504, K533 
GML 2765 12 0.669 1.94 (36.36%) 3.66E-02 S107 
DEFB1 1672 5 0.581 42.67 (1.5%) 1.14E-03 R61 
CLEC4M (L-SIGN) 10332 8 0.538 5.28 (9.83%) 3.45E-04 A88 
Control genes        
IFNA8 3445 5 1.334 9.36 (6.89%) 6.98E-03 R45 
PHYHD1 254295 5 1.220 10.80 (5.19%) 9.64E-03 - 
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4.4 Applications of evolutionary genetic results to other studies 
 
The data generated by these evolutionary and comparative genetics studies was 
used in additional work. 
 
1. Calculation of nucleotide substitutional pattern of the viral restriction factor TRIM5α 
allows estimation of the ancestral states of the coding sequence. It has been possible 
to reconstruct these ancestral states for TRIM5α and test their specificity in vitro 
against (modern) HIV-1 and five other retroviruses. This, to better understand the 
evolution of antiretroviral specificity patterns in primates, in particular along the 
lineage leading to humans. The results are presented in the article “Antiretroviral 
Activity of Ancestral TRIM5α” 65. The study proposes a statistically significant 
reduction of HIV-1 restriction by the reconstructed TRIM5α variants (representing 25 
million years of evolution) from the common ancestor of old world monkeys and 
hominoids toward the human variant. The ancestral TRIM5α showed various patterns 
of restriction capacities against other (modern) retrovirus tested. This study also 
reveals novel functionally relevant amino acid variants for virus restriction. 
 
2. Evolutionary data allowed a more comprehensive evaluation of 
TRIM5α polymorphic residues in humans. These were tested for their effect on HIV-1 
replication. Common variants of TRIM5α have no effect or modest effect on HIV-1 
disease progression. These variants are remote from clusters of positive selection in 
the primate lineage. The results are presented in the article “Role of common human 
TRIM5α variants in HIV-1 disease progression” 66. 
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3. Evolutionary information was included in the structural analysis of APOBEC3G. 
Clusters of positive selection were maped to a 3 D structural model of APOBEC3G 
and assessed in the context of protein domains important for packaging of 
APOBEC3G into virions. This model proposes two main clusters with residues under 
positive selection exposed at the surface. One of the main clusters is at a distinct 
location from that of the functionally relevant amino acids. The second cluster 
overlaps with a cluster that includes the important residues D128 and P129, related 
with the disruption of APOBEC3G packaging into HIV-1. This results are presented in 
the article “Model Structure of Human APOBEC3G” 67. 
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5. Discussion and perspectives: 
 
5.1 Lessons learned 
 
The progress of my thesis work reflects the successive developments in the field, in 
particular the growing number of genetic information, and the feasibility of 
amplification and resequencing of gene orthologs. 
 
The first gene targets proved to be excellent models for the power of evolutionary 
genetics to identify domains important for retroviral restriction. In the case of TRIM5α, 
evolutionary approaches had the same level of precision in identifying key residues 
as extensive biological assessment through the construction of chimeras and site-
directed mutagenesis gene variants. In the case of APOBEC3G, analysis offered a 
more general pattern of residues under selective pressure across the gene, and 
however, enough information to identify residues in the interaction domain with HIV-1 
Vif. 
 
The next steps of my research brought me to test how general this approach could 
be if applied to other proteins that are known to interact with one or more pathogens. 
For this, the choice was the DC-SIGN family of proteins, because of their role in the 
recognition of a range of pathogens. The KA/KS values were in the range of 0.3 to 0.5, 
considered as values indicating a process of purifying selection. The absence of 
strong signs of positive pressure limited the capacity to identify relevant domains. 
These results made me contemplate the interest of assessing a second family of 
genes involved in the recognition of molecular patterns from multiple pathogens. 
Study of the TLR family confirmed the image generated by the analysis of the DC-
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SIGN family: a similar range of KA/KS values, and lack of precision to identify 
particular regions or amino acids under positive selection. Thus, the initial results 
would suggest that only under the unique conditions of strong positive selection 
would the evolutionary genetic analysis help identify key mutational events of interest 
of the understanding of the underlying biological process.  
 
The possibility to generalize this approach, with the goal of understanding its 
potential, was limited by the need to generate high quality of sequence across the 
various primate lineages. This limitation was in part lifted by the new availability of 
complete genomes of primates representing the main branches: Hominids, Old and 
New World monkeys. I first assessed the precision of analyzing 5 primates (human, 
chimpanzee, bornean orang-utan, rhesus monkey and common marmoset) versus 
work with a larger set of eleven primate species. The results were encouraging, as 
they allow the similar estimation of KA/KS value averaged over the entire tree. 
However, it was also apparent that a reduced number of primates would seriously 
decrease the precision in the identification of regions under positive selection, and of 
particular residues. 
 
These limitations notwithstanding, I undertook a large scale analysis of 137 genes 
involved in the HIV-1 life cycle and pathogenesis, and of 100 control genes in the 5-
primate set. The large scale analysis confirmed the original impression from the 
analysis of TRIM5α and APOBEC3G: that evolutionary genetics would identify, 
without a priori, critical residues in the interaction with pathogens. Indeed the analysis 
identified residues in at least two genes/proteins (CD4 and CCR3) that had already 
been shown involved in HIV-1 biology. Second, while the average KA/KS value was 
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shown to be 0.2, genes/proteins of the innate immunity consistently exhibited a KA/KS 
average value of 0.4, which then appears as characteristic for these families of 
genes/proteins. The large scale study also characterized a theoretical “mutational 
space” for genes involved in cellular activities needed for the viral replication. In 
particular, genes involved in transcription and late phases of the viral replication cycle 
were under significantly stronger purifying selection than the average across control 
genes. We hypothesize that strongly conserved genes in primate evolution will be 
unlikely to carry (common) polymorphism in modern humans that would result in 
interindividual differences in disease susceptibility. 
 
5.2 Perspectives 
 
As discussed above, one of the goals of genetic evolutionary studies would be to 
guide functional analysis of relevant proteins. The outcome of the large scale 
analysis illustrates this point by the identification of eleven proteins that have amino 
acids under positive selective pressure. The nature of the protein would guide the 
most appropriate empirical approach. One of the most innovative approaches is the 
possibility to use the evolutionary sequence data for ancestral reconstruction. This 
was done for TRIM5α where we constructed and tested five ancestral TRIM5α 
variants on the lineage leading to modern humans and spanning 25 million years of 
primate evolution. The study underscored the feasibility of such approach and 
resulted in challenging observations: the identification of an ancestral TRIM5α 
capable of restricting modern HIV-1, and the capacity of this approach to identify new 
functional residues. This type of approach is now applied to the analysis of 
APOBEC3G in the laboratory coupled to the reconstruction and analysis of ancestral 
retroviruses. 
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A second perspective relates to the increasing availability of complete genomes. This 
would increasingly improve the precision of the analysis, and will also lead to a more 
systematic genome-wide cataloguing of genes relevant (or possibly relevant) to a 
disease. The availability of data from multiple members of a same species will also 
help precision. The release of members belonging to specific groups, for example the 
orang-utan and the unexpected Neanderthal genomes will improve the analysis of 
human-specific selection. In addition, the expected release of the genomes of 
prosimians will allow the estimation of ancestral proteins up to 40 million years ago. 
 
A third perspective concerns the modelling of co-evolution. We have initiated the 
analysis of evolution of the HIV-1 viral capsid and of the cognate TRIM5α host 
partner. These approaches will bring the red-queen principle to the field of functional 
testing. 
 
A fourth perspective relates to the expected improvements in informatic tools, 
including the use of better programs for alignment of sequences, better coverage of 
genomes, and better approaches to the handling of indels, paralogous genes and 
copy number variation. 
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